Exposure-adjusted event rates of malignancy (excluding NMSC), adjudicated MACE and VTE in patients receiving continuous upadacitinib or adalimumab
| Event | Continuous UPA 15 mg QD +MTX (n=398; PY=994.1) (95% CI) (events) | Continuous ADA 40 mg EOW +MTX (n=168; PY=373.0) (95% CI) (events) |
| Malignancy (excluding NMSC)* | 0.8 (0.3 to 1.6) (8) | 1.1 (0.3 to 2.7) (4) |
| MACE (adjudicated)* | 0.1 (0.0 to 0.6) (1) | 0.5 (0.1 to 1.9) (2) |
| VTE (adjudicated)* | 0.2 (0 to 0.7) (2) | 0.8 (0.2 to 2.4) (3) |
*Exposure-adjusted incidence rates were the same as exposure-adjusted event rates for malignancy, MACE and VTE.
ADA, adalimumab; AE, adverse event; EOW, every other week; MACE, major adverse cardiovascular event; MTX, methotrexate; NMSC, non-melanoma skin cancer; PY, patient years; QD, once daily; UPA, upadacitinib; VTE, venous thromboembolism.